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Abstract
Background: Most experimental stroke research is carried out in rodents, but given differences between rodents and
human, nonhuman primate (NHP) models may provide a valuable tool to study therapeutic interventions. The authors
developed a surgical method for transient occlusion of the M1 branch of middle cerebral artery (MCA) in the African green
monkey to evaluate safety aspects of intravenous infusion of mesenchymal stem cells (hMSCs) derived from human bone
marrow.
Methods: The left Sylvian fissure was exposed by a small fronto-temporal craniotomy. The M1 branch of the MCA was
exposed by microsurgical dissection and clipped for 2 to 4 hours. Neurological examinations and magnetic resonance
imaging (MRI) were carried out at regular post-operative course. hMSCs were infused 1 hour after reperfusion (clip release)
in the 3-hour occlusion model.
Results: During M1 occlusion, two patterns of changes were observed in the lateral hemisphere surface. One pattern
(Pattern 1) was darkening of venous blood, small vessel collapse, and blood pooling with no venous return in cortical veins.
Animals with these three features had severe and lasting hemiplegia and MRI demonstrated extensive MCA territory
infarction. Animals in the second pattern (Pattern 2) displayed darkening of venous blood, small vessel collapse, and
reduced but incompletely occluded venous flow and the functional deficit was much less severe and MRI indicated smaller
infarction areas in brain. The severe group (Pattern 1) likely had less extensive collateral circulation than the less severe
group (Pattern 2) where venous pooling of blood was not observed. The hMSC infused animals showed a trend for greater
functional improvement that was not statistically significant in the acute phase and no additive negative effects.
Conclusions: These results indicate inter-animal variability of collateral circulation after complete M1 occlusion and that
hMSC infusion is safe in the developed NHP stroke model.
Citation: Sasaki M, Honmou O, Radtke C, Kocsis JD (2011) Development of a Middle Cerebral Artery Occlusion Model in the Nonhuman Primate and a Safety
Study of I.V. Infusion of Human Mesenchymal Stem Cells. PLoS ONE 6(10): e26577. doi:10.1371/journal.pone.0026577
Editor: Niels Olsen Saraiva Ca ˆmara, Universidade de Sao Paulo, Brazil
Received June 29, 2011; Accepted September 29, 2011; Published October 24, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported in part by the Medical and Rehabilitation and Development Research Services of Department of Veterans Affairs (VA); the VA
Spinal Cord Injury Translational Collaborative Consortium for Regenerative Medicine; the National Institutes of Health [NS43432 to J.D.K.]; the National Multiple
Sclerosis Society [RG2135, CA1009A10 to J.D.K.]; the Paralyzed Veterans of America Research Foundation [2469 to M.S.]; and the Japanese Ministry of Education,
Science, Sports and Culture [19591691; 20390388; 20591717 to O.H.]. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Jeffery.Kocsis@yale.edu
Introduction
Cellular interventional approaches to improve functional
outcome after middle cerebral artery (MCA) occlusion in the
rodent have yielded encouraging results. For example, direct or
intravenous administration of mesenchymal stem cells (MSCs) and
genetically modified MSCs reduce infarction volume and improve
functional outcome after cerebral ischemia induction in the rodent
[1–17]. While these preclinical studies suggest the potential of cell-
based therapies to improve outcome in clinical stroke studies,
direct extrapolation from the rodent to human cannot be made
given issues of species differences and scale. Ideally, demonstration
of efficacy in a nonhuman primate (NHP) stroke model would
engender greater confidence in the approach since the organiza-
tion of the vascular and sensory and motor systems in the brain are
more similar amongst primates [18]. However, a limited number
of stroke studies have been carried out in the NHP using a
relatively small number of animals [19–23] and the natural course
of stroke in the NHP has not been fully studied. In these various
models of MCA stroke induction in the NHP there is considerable
variation in both lesion size and functional outcome. These
differences have been attributed to variation in collateral
circulation between NHPs [21] similar to that which can occur
in humans.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26577In this study, we first describe a NHP stroke model where the
left M1 segment of the MCA was completely occluded with an
aneurysm clip for several hours in the African green monkey
(n=11). The animals were given regular neurological examina-
tions and MRI scans before and during the post-infarction period.
Two groups of animals were observed in terms of outcome; severe
long lasting hemiplegic (Pattern 1) and modest initial hemiplegic
with near complete recovery (Pattern 2). The second objective of
the study was to determine the safety of intravenous infusion of a
well-defined population of human MSCs (hMSCs) in the acute
phase of stroke in the NHP (n=11). Outcome was evaluated with
neurological examinations and MRI scans. There were no adverse
events in the hMSC treated group suggesting safety of the cell
infusion protocol.
Results
Initial series of transient MCA occlusion model in the NHP
In the initial series of experiments to evaluate outcome of the
cerebral infarction model in the African green monkey (n=11)
(Table 1, 2), a craniotomy was performed to expose the left
Sylvian fissure (See Methods and Figure 1). The M1 branch of
the MCA was exposed in the Sylvian fissure (Figure 1A) and was
occluded with a vascular microclip (Figure 1B, C; n=10). One
animal (#9) had craniotomy alone with no M1 clip for control.
Immediately after clipping the M1 portion of the MCA, the
vasculature over the lateral margin of the fronto-parietal region
darkened (Figure 1E; arrowheads), small vessels collapsed and
a variable degree of reduced cortical blood was observed. In four
of the ten NHPs in this set of experiments, venous blood flow was
virtually completely blocked. A back and forth movement of a pool
of blood within the vessel was observed with vascular brain
pulsation, but did not flow to the superior sagittal sinus (Pattern 1).
In six of the 10 infarcted animals clipping of the M1 resulted in
darkening of cortical blood supply, small vessel collapse, but a slow
flow of reduced venous return was observed (Pattern 2). Removal
of the clip was followed by return of appropriate coloration of the
blood in the cerebral vessels, small vessel reperfusion and return of
general blood flow (Figure 1F). The difference in venous return is
likely the result of animals with rich and with poor collateral
circulation. Throughout the study, animals with no observed
venous return (Pattern 1) are referred to as ‘‘collateral-poor’’ and
those with reduced but observable venous return (Pattern 2) as
‘‘collateral-rich’’ based on this observation during surgery.
MRI (FLAIR, axial plane) obtained from 2-hour occlusion
animalsat daythreearepresented inFigure 2. High intensityareas
indicating infarcted lesion were localized primarily in the basal
gangliaand intheMCAterritoryincludingcortex.Strokevolumeof
each animal demonstrated smaller infarcted areas [Figure 2,
lower panels;2 3 . 9 67.5 cm
3 (mean 6 SEM)] in the collateral-
rich group as compared to the collateral-poor group [Figure 2,
upper panels; 103.9618.7 cm
3 (mean 6 SEM); p=0.0032, t
test]. There was a 23% decrease in the collateral-rich group. This
was confirmed with a nonparametric test, the Mann-Whitney U test
(p=0.029). MRI could not be performed from an animal with 2-
hour occlusion (#8) because of motion artifact. No infarcted areas
were observed in the animal with craniotomy alone (#9). These
data are summarized graphically in Figure 3. Examination of the
gross brain of a representative animal in the collateral-poor group
indicated severe necrosis of the left MCA territory at 1 year
(Figure 4E, F), but virtually no gross changes could be observed in
the collateral-rich animals (Figure 5E, F). In one NHP (#10), we
increased the occlusion time to four hours from two hours and
strokevolumeatday3was43.97 cm
3.Althoughthisanimalshowed








1 F Unk 4.6 2 hours Poor 19 M
2 F Unk 4.5 2 hours Poor 18 M
3 F 2 5.1 2 hours rich 3 M
4 F Unk 5.9 2 hours Poor 3 days
5 F Unk 4.6 2 hours rich 1 M
6 F 11 5.3 2 hours Poor 13 M
7 F 8 4.2 2 hours rich 2 weeks
8 F 9 5.5 2 hours rich 10 days
9 F 8 5 No craniotomy 4 M
10 F Unk 4.9 4 hours rich 2 weeks
11 M 8 6.9 2 hours rich 2 M
Unk=unknown.
doi:10.1371/journal.pone.0026577.t001
Table 2. Developing model parameters.
Animals HR pre MABP pre BT pre SaO2 pre HR MABP BT SaO2 HR post MABP post BT post SaO2 post
1 107 55 96.8 100 108 N/A 97.6 100 105 51 98 100
2 110 52 97 100 112 57 96.3 94 117 56 99 99
3 115 78 95 98 118 81 95.4 98 112 82 96.5 99
4 114 68 96 100 121 60 97 100 116 56 97 100
5 116 54 97 99 120 55 97.2 99 132 55 96.8 100
6 150 60 99 99 156 56 98 99 147 59 98 100
7 139 59 97 99 134 60 98.7 100 135 52 98 99
8 142 54 100 98 145 57 101 97 147 58 99 100
9 126 55 96 99 118 58 95.6 100 115 57 97 99
10 115 56 97 99 120 58 94.4 99 128 54 97 99
11 103 64 97 99 95 66 94.1 98 98 63 96 98
HR=heart rate; MABP=mean arterial blood pressure; BT=body temparature; SaO2=oxygen saturation.
doi:10.1371/journal.pone.0026577.t002
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the collateral-rich group described above, the general health status
of this animal was very poor as compared to other 2-hour occlusion
animals, and the Yale Veterinary Clinical Services (VCS)
recommended to euthanize after 2 weeks of stroke induction.
Effects of hMSC infusion of animal health, stroke volume
and motor performance
After completion of the initial series to assess the lesion model,
hMSCs or human serum was infused into the animals 1 hour after
clip release (n=11). Both groups were immunosupressed with
Cyclosporin A (See Methods). Occlusion time was 3 hours in the
safety study for both the cell infusion and human serum groups
(Tables 3, 4) because previous studies using Macaca demonstrated
that 3 hours of occlusion is sufficient to cause a permanent stroke
in the NHP [21,24]. Ten animals with collateral-rich circulation
were used for the analysis to compare the neurological scores and
stroke volume. To evaluate whether hMSC intravenous infusion
produced adverse effects, we assessed the general vital signs of each
animal prior to surgery and monitored them after surgery on a
Figure 1. Clipping of M1 portion of left middle cerebral artery with small vascular clip. (A) The M1 region (arrow) of the MCA was
exposed by a retractor deep in the Sylvian fissure. Frontal is frontal lobe, Temporal is temporal lobe. (B) A small vascular clip was applied to the M1
portion. (C) MCA was occluded by a clip. (D) Before clipping, the color of venous blood was normal. (E) Darkning of cortical veins was observed
during occlusion of MCA. (arrowheads).( F) After releasing the clip, the color of venous blood returned to normal.
doi:10.1371/journal.pone.0026577.g001
Figure 2. MRI of model development (initial) series. Axial images of MRI FLAIR at day 3 obtained from all animals in the model development
(initial) series. Upper panels (#1, #2, #4, #6) are collateral-poor animals, lower panels (#3, #5, #7, #11) are collateral-rich animals. High intensity
area indicating cerebral infarction is primarily located in the left basal ganglia in collateral-rich animals. There was more extensive infarction areas in
the MCA territory including cortex in collateral-poor animals.
doi:10.1371/journal.pone.0026577.g002
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tion were evident in any hMSC infused animals during the
survival period except the expected right motor deficits that either
did not worsen or improved, which was qualitatively similar to
control. It should be noted that one animal (#21) in the serum
group died at day 3 due to an unknown reason and another
animal (#13) in the serum group became comatose and had to be
euthanized at 7 days post-surgery. Autopsies were obtained by
Yale VCS group and showed no obvious medical complications in
their organs, but they displayed massive hemorrhagic infarction.
MRIs from all NHPs with collateral-rich at 3 days, 7 days, 1
month, 5–6 months and 12 months after surgery with serum or
hMSC infusions are shown in Figure 6 and 7 respectively. As
presented in Figure 8, the stroke volumes of hMSC infusion
group were smaller than the serum infusion group at day 3
(101639.13 cm
3; 70.14623.63 cm
3; p=0.54, t test), day 7
(80.8635.66 cm
3; 61.27622.37 cm
3; day 7; p=0.65, t test), 1
month (41.63625.79 cm
3; 24.44615.99 cm
3; p=0.59, t test), 6
months (24.63617.95 cm
3; 16.78613.84 cm
3; p=0.74, t test) and
12 months (20.02615.73 cm
3; 15.85614.13 cm
3; p=0.84, t test).
Repeated Measures ANOVA indicated no interaction between the
two groups. Although a trend was observed, comparison of the
stroke volume between hMSC and serum infusion groups at all
time points did not reach statistical significance. This was
confirmed with the Mann-Whitney U test.
MRI (Figure 9A) and a macroscopic image (Figure 9B)
obtained from a representative animal (#14) in the hMSC infused
group demonstrated small necrotic cavity in the left basal ganglia.
HE staining (Figure 9C–G) from a same animal revealed
infiltration of the inflammatory cells in the formed cavity, fibrous
gliosis in the wall of the cavity and no tumor formation in and
around the cavity, even after one year. Obvious survival of the
hMSCs was not observed with anti-human nuclei staining (data
not shown).
Neurological scores for hMSC and serum infusion groups with
collateral rich animals were tested at day 1, day 3, day 7, day 14, 1
month, 6 months and 12 months after surgery (Figure 10). All
experimental animals exhibited a gradual improvement in
Neurological score. Statistical analysis indicated that the Neuro-
logical scores of the hMSC infusion group were lower than the
serum group at day 1 (10.7567.80; 20.5612.97; p=0.219, t test),
day 3 (6.064.08; 8.7565.73; p=0.464, t test), day 7 (3.063.16;
4.2564.03; p=0.642, t test), day 14 (2.2563.20; 2.2563.30;
p=1,t test), day 30 (0.62560.75; 1.7562.36; p=0.3399, t test), 6
months (0.560.57; 1.062; p=0.647, t test) and 12 months
(0.2560.5; 1.062; p=0.494, t test) after surgery respectively.
Although a trend was observed, these differences did not reach
statistical significance. This was confirmed with the Mann-
Whitney U test. Repeated Measures ANOVA indicated no
interaction between the two groups.
Discussion
We first describe a stroke model in the African green monkey
(old world monkey) that can be induced by a microsurgical
procedure via open supratentorial craniotomy and microclip
occlusion of the M1 portion of the MCA. Two general groups of
animals were observed in terms of functional outcome and
ischemic volume. One group (Pattern 1) displayed severe
hemiparesis, and MRI and gross brain examination demonstrated
more extensive cerebral infarction in the MCA territory including
cortex. The second group (Pattern 2) displayed minor hemiparesis,
and MRI exhibited a localized infarcted lesion primarily in the
basal ganglia. Direct visualization of the blood ‘‘pooling’’ in
cortical veins during M1 clipping provided a clear indication of the
collaterality in the brain. In the more severe lesions (Pattern 1),
venous return was blocked during clipping, but in the less severe
lesions (Pattern 2) venous return was greatly slowed, but could be
visualized by microscopic examination of surface veins during
surgery. This suggests that the degree of collateral circulation
varied in the animals, with the most severe lesions being in animals
with poor collateral circulation. We thus grouped the animals as
collateral-rich and collateral-poor based on this observation during
surgery. The differences between the two groups are not likely the
result of incomplete occlusion by the clip. In one NHP where
collateral rich circulation was observed after M1 clipping, the
animal was immediately euthanized. Observation of the M1 clip at
the clip site in the Sylvian fissure revealed a complete occlusion of
the vessel indicating incomplete clipping was not the reason for
lesion variability. Thus, variance in collateral circulation between
the NHPs likely explains the differences in lesion severity. We tried
to measure cerebral blood flow with laser doppler flowmetry
(Laser Doppler ALF21, ADVANCE CO., LTD., Tokyo, Japan) in
some animals, however, the laser doppler flowmetry provided
information on the relative decrease in blood flow at only a single
point, thereby making it difficult to evaluate the collateral
circulation in the African green monkey’s brain and determine
whether the territory is fully or only partially occluded as described
in a canine stroke model [25]. Future studies with laser Doppler
scanner or advanced MRI imaging will be required. We would
stress that there are limitations on extracting conclusions from the
model development (initial) series. In this study, we used eleven
animals for model development series and found two patterns of
Figure 3. Scattered plots of stroke volume from model
development series (n=4/group). Scattered plots show the stroke
volume measured with axial images of MRI FLAIR at day 3. The stroke
volume of collateral poor group (103.9618.7 cm
3) is greater than the
collateral rich group (23.967.5 cm
3; p=0.0032). Each black symbol with
number corresponds to the animal number in Table 1. Long symbols
show averages. Given the small size, this was confirmed with a
nonparametric test, the Mann-Whitney U test (p=0.029).
doi:10.1371/journal.pone.0026577.g003
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compared to the previous NHP stroke studies [19–23], there were
budgetary and ethical issues to use NHP compared to rodent
studies in general. Thus we were not able to increase the number
of experimental animals to provide consistent lesion volumes
which are observed in the rat MCA occlusion model [26].
To help address barriers in the translation of animal studies to
human clinical trials, the Stroke Therapy Academic Industry
Roundtable (STAIR) publication provided recommendations for
the preclinical development of acute ischemic therapies [27]. The
STAIR reported in their initial publication that there are no
standardized, well-accepted models of stroke recovery in primates,
although limited experience exists with baboons [18]. A panel of
investigators in spinal cord injury research commented that studies
in NHP can probe the effects of therapy-induced neural plasticity
on multiple aspects of functional recovery with a refinement that
cannot be attained in rodents and recommended the use old world
monkeys [28]. One reason to use old world monkeys is that they
have the advantage of being easily trained to assess function, and
the projection patterns of its corticospinal tract (including direct
Figure 4. A representative animal of collateral poor NHP (2 hour occlusion of MCA). Axial (A) and coronal (B) MRI FLAIR at day 3
demonstrate extensive high intensity areas located in the left MCA territory. Axial (C) and coronal (D) image of MRI T2WI at 1-year post-stroke
demonstrated that high intensity areas remained. Gross brain anatomy revealed obvious lesion on the lateral surface of the brain 1 year after stroke
(E, F).
doi:10.1371/journal.pone.0026577.g004
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areas are more similar to those of humans.
Over the past 10 years, in addition to the microsurgical
approach via open craniotomy or transorbital approaches [29,30],
photochemical [19,23], and chemical [20] approaches have been
developed in NHPs. Several stroke models in medium-sized
animals such as pigs [31], sheep [32] and canines [25] also have
been developed. Recent advances in interventional neuroendo-
vascular technique have made possible the establishment of a
stroke model in macaques [21]. An advantage of this endovascular
technique is that it is less invasive compared to our surgical
approach, but there are still some complications, such as potential
arterial dissection [33] or incomplete occlusion. In rodents, the
intraluminal thread model of MCAO is widely used and produced
with blind insertion of the microsuture to occlude the origin of the
MCA [26,34]. However, to carry out a similar technique in a
NHP, a fully equipped neuroradiological facility with a highly
skilled endovascular neurosurgeon utilizing a fine microcathether
for intraluminal occlusion would be needed [21].
While we and others [29] have employed a supratentorial
craniotomy approach which adds an additional potential surgical
risk as opposed to an endovascular approach, clinical experiences
indicate that it is relatively safe. Only 0.8% of 4,992 patients who
underwent intracranial procedures experienced postoperative
Figure 5. A representative animal of collateral rich NHP (2 hours occlusion of MCA). Axial (A) and coronal (B) MRI FLAIR at day 3
demonstrate high intensity area located primarily in the left basal ganglia. Axial (C) and coronal (D) image of MRI T2WI at 1-year post- stroke
demonstrated high intensity area is reduced. Gross brain anatomy revealed no obvious lesion in the surface of the brain at 1 year after stroke (E, F).
doi:10.1371/journal.pone.0026577.g005
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could be attributed to the craniotomy. While the craniotomy
appears to pose low risk in the direct clip model, variation in
collateral circulation in the NHP for any model thus far described
leads to variability in outcome between animals complicating
comparison between treated and non-treated groups, despite
presenting a model more similar to stroke in humans. Indeed, de
Crespigny et al. (2005) who used the endovascular approach with
3 hours occlusion in macaques also attribute the relatively good
outcome, despite angiographically confirmed occlusion by micro-
catheter tip, as being due to good collateral circulation [21].
Intravenous infusion of autologous hMSCs is a potentially
promising approach for stroke therapy. Rodent work suggests
reduction of stroke volume and functional recovery is induced
after intravenous infusion of hMSCs [1–3,6,8,11,12,15,16].
Current thinking is that the potential beneficial effect of MSCs
in various experimental models of CNS injury is not from
neuronal or glial differentiation but from release of trophic factors
which may provide for neuroprotection [36–38], induction of
axonal sprouting [39], neovascularization [12], and immunomod-
ulation [40,41]. In rodent studies, infusion of hMSCs genetically
modified to produce various trophic and angiogenic factors leads
to reduction in lesion volume and improved functional outcome
[3,8,12,42–45]. Several institutions including us have carried out
Phase I clinical trials with intravenous autologous bone marrow
transplantation for stroke patients and have reported preliminary
results [46–49].
Phinney and colleagues performed safety studies of direct
hMSC injection in the right caudate nucleus of healthy adult
rhesus macaques and reported no adverse effects [50,51]. We
studied the safety of intravenous infusion of hMSCs in NHPs after
stroke induction. The cells were delivered in the acute phase at
1 hour after clip release. No adverse effects were observed in the
hMSC group as compared to animals infused with human serum
alone. Importantly, MRI and histological examination of the
infarction site indicated no tumor formation. HE staining revealed
infiltration of macrophages in the formed cavity and fibrous gliosis
in the wall of the cavity, however, survival of the hMSCs was not
identified with anti-human nuclei staining. Both the serum and the
hMSC groups showed functional recovery and tendency to reduce
in infarction volume over time. Differences of infarct volume
evaluated by MRI and neurological improvement observed in the
hMSC and serum groups did not reach statistical significance, but
a trend was observed. It should be noted that neuroprotective
Table 3. Safety Study animals summary.
Animals Sex Age Body weight MCAO Duration Collateral Treatment End point
12 M Unk 5.7 3 hours rich Cells 12months
13 F 8 5.5 3 hours rich Serum 7 days
14 F Unk 4.1 3 hours rich Cells 12months
15 F 12 5.6 3 hours rich Serum 12months
16 M Unk 6.2 3 hours poor Cells 12months
17 M Unk 5.5 3 hours rich Cells 12months
18 M Unk 5.3 3 hours rich Cells 12months
19 F Unk 4.9 3 hours rich Serum 12months
20 F Unk 4.1 3 hours rich Serum 12months
21 F Unk 4.5 3 hours rich Serum 4 days
22 F Unk 5.2 3 hours rich Serum 12months
Unk=unknown.
doi:10.1371/journal.pone.0026577.t003
Table 4. Safety Study animals parameters.
Animals HR pre MABP pre BT pre SaO2 pre HR MABP BT SaO2 HR post MABP post BT post SaO2 post
12 119 52 96.3 99 125 48 96.3 99 126 51 97.7 99
13 120 50 96 99 122 52 95 95 124 54 97 100
14 130 53 95.4 98 129 47 97.1 99 133 55 98 99
15 134 45 98.2 100 152 51 100 98 138 49 97 100
16 124 49 97.6 100 110 56 98.4 100 118 53 97 99
17 139 55 96.5 97 139 52 101.4 99 136 54 97 99
18 112 52 98.5 98 118 52 98.7 98 115 53 98 100
19 140 58 98 99 145 53 98.9 99 143 48 96.8 100
20 128 59 99 100 123 56 99 97 129 58 97.8 100
21 162 57 98.5 99 165 58 98.7 95 150 54 96.8 97
22 135 69 98 100 132 72 99.4 99 130 65 96.9 98
HR=heart rate; MABP=mean arterial blood pressure; BT=body temparature; SaO2=oxygen saturation.
doi:10.1371/journal.pone.0026577.t004
hMSCs Intravenous Infusion in NHP Stroke
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26577effects by cyclosporine may participate in the reduction of stroke
volume and functional improvements in both groups. Although it
is not clear the reason that no animals died in the initial model
development group but two animals with human serum infusion
had severe hemorrhagic complications lead to death within 7 days
in the safety study group, it should be noted that the time of
purchase for the animals were different between two experimental
series. It is possible that there were unknown differences of
environmental, genetical and growth history.
In summary, this study shows that surgical occlusion (clipping)
of the M1 region of the MCA for several hours results in two
classes of lesion severity; mild and severe. The mild lesion animals
have greater collateral circulation than the severe group. MRI
analysis indicated that the majority of the animals with MCA
occlusion displayed mild neurological symptoms and relatively
small infarction sites in deep structures including the basal ganglia
with little cortex involvement. The severe group had extensive
contralateral hemiplegia and necrosis in the MCA territory.
Future studies will be required to predict the collateral circulation
quantitatively using intra-operative electroencephalography and/
or somato-sensory evoked potential recording in addition to the
direct visualization of the blood ‘‘pooling’’ in cortical veins during
M1 clipping reported in this study. In addition to the predicting
the collateral circulation, the measurement of brain tissue
reorganization with perfusion-weighted MRI and/or diffusion
tensor MRI might be useful to understand vascular and neuronal
remodeling after stroke in NHP. Comparison of neurological
function and lesion volume between animals infused with hMSCs
or human serum without cells indicated no statistical difference in
outcome although a trend was observed. The variability in
functional outcome in this and other studies in NHP is likely the
result of variable collateral circulation. This variability is certainly
a complicating factor for studies designed to assess efficacy.
However, with regard to safety, there were no adverse events
observed in the NHPs infused with hMSCs. Additional studies will
be necessary to increase the number of animals to determine if the
Figure 6. MRI FLAIR images of hMSC infused NHPs. Axial images of available MRI of hMSC infused NHPs at day 3, day 7, 1 month, 6 months and
12 months. #12, #14, #17 and #18 correspond to the animal number in Table 3.
doi:10.1371/journal.pone.0026577.g006
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neurological scores in the hMSC group may reach significance.
Materials and Methods
Cell preparation and characterization
This study was conducted according to the Declaration of
Helsinki guidelines and was approved by the Institutional Review
Board at Sapporo Medical University. We received written
informed consent from all participants. hMSCs were prepared
by using a previously described method with minor modifications
[52]. Briefly, peripheral blood (200 ml) for human serum and bone
marrow (30 ml) were collected from healthy volunteers. Bone
marrow was obtained from the posterior iliac crest under local
anesthesia, and was diluted with Dulbecco’s modified Eagle’s
medium, (Mediatech Inc, Manassas, Virginia) supplemented with
10% human serum, 2 mM L-glutamine (SIGMA-ALDRICH, St.
Louis, Missouri), 100 U/ml penicillin-streptomycin (SIGMA-
ALDRICH, St. Louis, Missouri), plated on 150-mm Tissue
Culture Dish (IWAKI, Tokyo, Japan), and incubated in a
humidified atmosphere of 5% CO2 at 37uC for several days.
hMSCs were selected by plastic adhesion and nonadherent cells
were eliminated by replacing the media. When cultures almost
reached confluency, the adherent cells were detached with
trypsin–EDTA solution (Mediatech Inc, Manassas, Virginia) and
subcultured at 1610
4 cells/ml. The hMSCs were expanded and
Figure 7. MRI FLAIR images of serum infused NHPs. Axial images of available MRI of serum infused NHPs at day 3, day 7, 1 month, 6 months
and 12 months. #13, #15, #19, #20 and #22 correspond to the animal number in Table 3. #13 died at day 7.
doi:10.1371/journal.pone.0026577.g007
hMSCs Intravenous Infusion in NHP Stroke
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less, targeting a cell number of 1.0610
8 cells. Cryopreservation
permitted detailed characterization of cells and pathogens, which
required several days prior to cell infusion and resulted in higher
cell viability (.95.2%).
Cell characterization and pathogen screening
Flow cytometric analysis of hMSCs was performed as previously
described [6,8]. Briefly, cell suspensions were washed twice with
PBS containing 0.1% bovine serum albumin (BSA). For direct
assays, aliquots of cells at a concentration of 1610
6 cells per
milliliter were immunolabeled at 4uC for 30 minutes with the
following antihuman antibodies: PE–conjugated CD34, CD45,
(Becton Dickinson Bioscience Pharmingen, San Jose, CA) and
CD105 (BioLegend, San Diego, CA). As an isotype-matched
control, mouse immunoglobulin G1 (Becton Dickinson Bioscience)
was used. Labeled cells were analyzed by a FACS Calibur flow
cytometer (Becton Dickinson) with the use of FlowJo software.
Figure 9. A representative hMSC infused NHP (#14). (A) Coronal image of MRI FLAIR obtained at 12 months after infusion of hMSCs
demonstrate high intensity area indicating stroke in the left basal ganglia and macroscopic image (B) shows necrotic cavity (arrow). Montage image
(C) of HE staining of frozen coronal sections revealed cavity formation in the basal ganglia and no tumor formation. High power images of HE staining
revealed infiltration of inflammatory cells in the cavity and fibrous gliosis in the wall of the cavity. No apparent infused hMSCs can be found in the
lesion area. Scale bars=1 mm (C), 200 mm( D–G).
doi:10.1371/journal.pone.0026577.g009
Figure 8. Summary of stroke volume from the safety study group. Measured stroke volume (day 3, day 7, 1 month, 6 months and 12 months)
in the hMSC and serum infused animals (A–E). Each small symbol with number represents a single animal. Long symbols are averages. Across all MRI
methods, there was an overall decrease in stroke volume, but no statistical significant difference. Summarized time-course is shown in F.
doi:10.1371/journal.pone.0026577.g008
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and propidium iodide staining. The expanded hMSCs were tested
for sterility; there was no evidence of bacterial, fungal, viral (ATL,
HBV, HCV, HIV), or mycoplasmal contamination, and endotox-
in level was under non-pathogenic level in all samples.
Animals
All animal experiments were performed at the Veterans Affairs
Connecticut Healthcare System in strict accordance with National
Institutes of Health guidelines for the care and use of laboratory
animals and in accordance with the recommendations of the
Weatherall Report. The Veterans Affairs Connecticut Healthcare
System Institutional Animal Care and Use Committee approved
all animal protocols (JK-0015). We also followed the Nonhuman
Primate Environmental Enrichment Program by the Veterans
Affairs Connecticut Healthcare System. Twenty-two young adult
African green monkeys (3.5–5.0 kg) of St. Kitts origin (Chlorocebus
sabaeus; Vervet; old world monkey) were used. Eleven of 22
animals were used for development of cerebral infarction model
(Table 1); the remaining eleven animals were used for safety study
of intravenous infusion of hMSC and immunosuppressed with
Cyclosporine A (Table 3). Using the animals in the initial series,
Figure 10. Neurological scores. Neurological score in the hMSC and serum infused animals at day 1 (A), day 3 (B), day 7 (C), day 14 (D), 1 month
(E), 6 months (F) and 12 months (G). Each small symbol with number represents a single animal. Long symbols indicate averages. There was an
overall significant decrease in Neurological score in hMSC group, but no statistical significant difference between the groups at all time points.
Summarized time-course is shown in H, I. Circled area in H is expanded in (I).
doi:10.1371/journal.pone.0026577.g010
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Scoring protocol (Table S1). Five out of eleven animals received
hMSC and the remaining six animals received serum from
human.
Anesthetic procedures
Animals were fasted for 12 hours prior to surgery. Anesthesia
was induced with Ketamine (10 mg/kg, IM) and Glycopyrrolate
(0.015 mg/kg, IM) and maintained via intubation with Isoflurane
(1.5–3%) and all efforts were made to minimize suffering. Lactated
Ringers (5–10 ml/kg/hour) was intravenously injected during
surgery [53].
Intra-operative monitoring
The animal was placed on a warm water re-circulating heating
pad, and covered with a blanket and a second warm water-heating
pad. Physiological parameters includes heart rate (HR), mean
arterial blood pressure (MABP), body temperature (BT) and
oxygen saturation (SaO2) were monitored constantly throughout
surgery and recorded every 15 minutes and remained normal
before, during and after the cell infusions, and there were no
statistically significant differences between groups. (Tables 2, 4).
Body temperature was measured constantly via a rectal probe.
MCA occlusion
The animals were fixed to a stereotaxic frame (Kopf, Tujunga,
CA) in supine position with their head rotated to the right side. A
left frontotemporal pterional approach was carried out. After
removal of bone flap, sphenoidal bone was drilled extraduraly.
The dura was opened and cut, and the arachnoid and trabecula
were dissected out to expose the M1 portion of MCA. A
microvascular aneurysm clip (B1 clip, FST, Foster City, CA) was
applied to the M1 (Figure 1A–C). During the occlusion period,
saline soaked gauze pads were applied to the brain surface. The
clip was released, dura sealed with fibrin glue and cranioplasty
with bone flap and skin closure were performed.
Intravenous administration
After completion of the development series, we performed the
safety study of the intravenous infusion of hMSCs into a NHP
stroke model. We decided to occlude MCA for 3 hours, release the
clip and waited for one hour to close the surgical field and skin.
Previous studies using Macaca demonstrated that 3 hours of
occlusion is sufficient to cause a permanent stroke in the NHP
[21,24]. On the day of infusion, cryopreserved hMSC or human
serum were thawed at the surgery room in a 37uC water bath.
After a total of four hours, hMSC (1.0610
7 cells/18 ml) or human
serum (18 ml) was intravenously infused for 30 min using a syringe
pump (Harvard Apparatus, Holliston, MA). The Cyclosporin A
regimen was 20 mg/kg the day prior to surgery, 15 mg/kg the day
of surgery, then 10 mg/kg daily; IM. Cell number was equivalent
to the dose that was effective in our previous studies with rodents
[6]. The order of delivering hMSC or serum was randomized. The
surgeons (M.S and J.D.K) did not know whether hMSC or serum
would infuse before and during surgery.
Post-operative care
The animals were placed on a warm water recirculation-heating
pad and covered with a blanket. The animals were monitored a
minimum of twice a day for one week or more often as needed.
After one week, they were checked at least once a day until stable
(eating/drinking normally). Animals unable to feed themselves
were hand fed by syringe with a liquid nutritional diet (Bio-Serve,
Frenchtown, NJ) until capable of eating themselves and given
Lactated ringers subcutaneously.
Neurological score
Blinded stroke testing using a clinical rating scale (Table S1)
was performed for the animals in the safety study of the
intravenous infusion of hMSCs before and at 1 day, 3 days, 7
days, 14 days, 1 month, 6 months and 12 months after MCAO.
The rating scale was modified from a previous study with
macaques [29]. Briefly, the state of consciousness, posture, gait
with home cage, stimulus and sensation response, extremity and
eye movements, as well as hand grasping ability were scored on a
point system with a score of zero corresponding to normal
behavior and a maximum score of 54 corresponding to severe
bilateral neurological impairment.
Magnetic Resonance Imaging
MRI scans for the animals in the safety study of the intravenous
infusion of hMSCs were performed before and at day 3, day 7,
month 1, months 5–6, and months 12 post-infarction. The animal
was placed in the scanner with the head immobilized. While in the
scanner, the animal was maintained on gas anesthesia (isoflurane)
and closely monitored. The scanning was performed in a 1.5T
MAGNETOM sonata MRI scanner (Siemens Medical Solutions
USA, Inc., Malvern, PA, USA). T1- and T2-weighted and Fluid
attenuated inversion recovery (FLAIR) images were obtained. The
images were obtained in axial and coronal planes. T2-weighted
images (T2WI) were obtained from a 3 mm-thick axial and
coronal section with 0.9 mm using a 180 mm field of view,
TE=67, TR=5000 ms, TI=50 ms, and reconstructed using a
1926256 image matrix. FLAIR were obtained from a 3 mm-thick
axial and coronal section with no gap using a 110 mm field of
view, TE=90 ms, TR=9000 ms, TI=2200 ms, and reconstruct-
ed using a 1616256 image matrix.
The ischemic lesion volume was calculated by a blinded
observer from axial plane of FLAIR image using iMac computer
(Apple, Cupertino, CA) running OS X and open-source DICOM
Viewer software (OsiriX Imaging Software, version 2.7.5, OsiriX
Foundation, Geneva, Switzerland). For each slice, the higher
intensity lesions in images where the signal intensity was 1.25 times
higher than the counterpart in the contra lateral brain lesion were
marked as the ischemic lesion area, and infarct volume was
calculated taking slice thickness into account [11].
Histology
The animals were prepared for histological preparation at the
end points (Table 1, Table 3). Intracardiac perfusion with saline
(2 liters) was followed by 4% paraformaldehyde (1 liter), and the
tissue was postfixed overnight [53]. HE staining was performed
and to identify the infused hMSCs, immunohistochemisty for anti-
human nuclei (dilution 1:30; Chemicon, Temecula, CA) was
carried out on 10 mm frozen sections. Negative controls were
performed on stroke-induced monkey brains with human serum
infusion.
Statistical analysis
All statistical analysis was performed using SPSS 18 for
Macintosh (SPSS, inc; Chicago, IL) and Origin software (version
8.1; OriginLab Corporation, Northampton, MA). Comparison
against control group was performed using the Student’s t-test.
Repeated measures analysis of variance (ANOVA) was conducted
for multiple comparisons. Given the small size, we confirmed all
results with the Mann-Whitney U-test [54].
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